Genmab A (GMAB) Goodwill & Intangibles (2018 - 2026)
Genmab A's (GMAB) quarterly Goodwill & Intangibles came in at $9.2 billion in Q2 2026, up 337.92% on a YoY basis from $2.1 billion in Q2 2025, and down 0.82% quarter-over-quarter from $9.3 billion in Q1 2026.
Analysis
Genmab A (GMAB) Goodwill & Intangibles (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Goodwill & Intangibles for 9 consecutive years, with $9.2 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Goodwill & Intangibles rose 337.92% year-over-year to $9.2 billion; the trailing twelve-month figure through Jun 2026 stood at $9.2 billion (up 337.92% YoY), and the FY2025 full-year result was $9.5 billion, up 6973.13% from the prior year.
- Goodwill & Intangibles fell to $9.2 billion in Q2 2026 per GMAB's latest filing, from $9.3 billion in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $9.5 billion in Q4 2025 and bottomed at $2.2 million in Q1 2024.
- Historically, Goodwill & Intangibles has averaged $2.0 billion across 5 years, with a median of $33.3 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles slumped 85.55% in 2024, then jumped 95125.23% in 2025.
- Over 5 years, Goodwill & Intangibles stood at $33.3 million in 2022, then soared by 151.26% to $83.7 million in 2023, then plunged by 85.55% to $12.1 million in 2024, then jumped by 78259.74% to $9.5 billion in 2025, then fell by 2.65% to $9.2 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $9.2 billion, $9.3 billion, and $9.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.23 Bn |
| Mar 31, 2026 | 9.30 Bn |
| Dec 31, 2025 | 9.48 Bn |
| Sep 30, 2025 | 2.10 Bn |
| Jun 30, 2025 | 2.11 Bn |
| Mar 31, 2025 | 2.11 Bn |
| Dec 31, 2024 | 12.10 Mn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.36 Bn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 83.70 Mn |
| Sep 30, 2023 | 10.65 Mn |
| Jun 30, 2023 | 12.27 Mn |
| Mar 31, 2023 | 12.66 Mn |
| Jan 1, 2023 | 21.00 Mn |
| Dec 31, 2022 | 33.31 Mn |
| Sep 30, 2022 | 19.00 Mn |
| Jun 30, 2022 | 22.02 Mn |
| Mar 31, 2022 | 25.08 Mn |
| Dec 31, 2021 | 26.67 Mn |